Enara Bio, an Oxford, UK-based biotechnology company developing cancer immunotherapies, raised $32.5M in Series B funding.
The round was led by Pfizer Ventures and M Ventures with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors. The Francis Crick Institute also joined as a new investor. In connection with the financing, Enara Bioās Board of Directors has been strengthened by the appointments of Rana Al-Hallaq, Partner at Pfizer Ventures, and Bauke Anninga, Investment Director at M Ventures.
The company intends to use the funds to advance its pipeline of TCR-based immunotherapies against novel and differentiated Dark Antigen targets for solid tumors.
Led by CEO and President Kevin Pojasek, Enara Bio has developed a platform called EDAPT to pioneer the discovery and validation of Dark Antigen targets for the development of cancer immunotherapies combining de novo bioinformatics databases with immunopeptidomics of tumor and healthy tissues alongside RNA in situ hybridization. This integrated approach enables the company to confirm presentation of Dark Antigens on the surface of human tumor cells, validate their cancer-specificity, and demonstrate homogenous intratumoral expression.
FinSMEs
03/10/2024